Tissue Therapies names CEO
Tuesday, 14 September, 2004
Tissue Therapies (ASX:TIS) has appointed Dr Stephen Mercer -- most recently managing director of Mercy Tissue Engineering -- as its new chief executive.
Dr Mercer is a registered medical practitioner, and has previously worked as general manager of Smith & Nephew Surgical and as a health industry specialist with IBM.
In recent laboratory trials, Tissue Therapies' VitroGro was shown to prompt higher rates of growth and migration of human skin cells than existing culture methods, which use foetal bovine serum or patient serum. VitroGro was also show to support the serum-free cultivation of corneal cells for the treatment of eye burns.
These results were presented by Queensland University of Technology researchers to the Australian and New Zealand Burns Association conference in Adelaide last week.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
